Mounjaro benefits and risks: what the evidence actually shows

What does Mounjaro actually do in the body, and how strong is the benefit evidence?

Tirzepatide activates two receptors at once (GIP and GLP-1) both involved in appetite regulation and blood-sugar control. By working on both pathways simultaneously, it slows the rate at which food leaves the stomach and reduces hunger more consistently across the day than older single-receptor medicines. That dual action is what makes it the only medicine of its type licensed in the UK for weight management.

The clinical evidence behind those mechanisms is detailed on our Mounjaro overview page, but the short version is this: in SURMOUNT-1, a 72-week phase 3 trial involving 2,539 adults with obesity and no diabetes, average weight reduction at the 15mg maintenance dose reached around 20–21%, with some analyses reporting up to 22.5%. A subsequent head-to-head trial, SURMOUNT-5, found tirzepatide produced greater average weight loss than semaglutide 2.4mg over the same duration. These figures come from controlled trial conditions with diet and activity support; real-world results vary, and no outcome is guaranteed.

One misconception worth putting to rest quietly: Mounjaro is not a quick fix that bypasses lifestyle change. The trial participants all received nutritional support alongside the medicine, and the licence itself requires treatment to be used alongside a reduced-calorie diet and increased physical activity. The medicine changes the biological signals around appetite; the rest still takes work.

NICE recommends tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related condition, with lower thresholds applying for some ethnic backgrounds under TA1026. Private prescribing follows the licensed criteria, which extend to BMI 27 or above with a qualifying condition.

What are the most common side effects, and when do they tend to ease?

The majority of side effects with tirzepatide are gastrointestinal. Nausea is the most frequently reported, followed by vomiting, diarrhoea, constipation, indigestion, reflux and burping. Fatigue, headache and dizziness also appear in the trial data, as do mild injection-site reactions at the site of the weekly injection.

These effects tend to be most pronounced when treatment starts and after each dose step upward, which is precisely why the prescribing schedule begins at 2.5mg and moves upward only when the body has adjusted. Eating smaller portions, avoiding very fatty or spicy food, and staying well hydrated all help. Most people find gastrointestinal symptoms settle over days to a couple of weeks at each new dose level, though this varies considerably between individuals.

The full side-effect breakdown for Mounjaro covers each symptom in more depth, including practical strategies. For those specifically troubled by loose stools or constipation patterns, there is dedicated guidance on switching between constipation and diarrhoea and on managing diarrhoea during treatment. The NHS tirzepatide medicines page is also a clear reference, published at nhs.uk/medicines/tirzepatide.

Which risks are rare but serious, and when should you get medical help urgently?

Acute pancreatitis is the risk that receives the most clinical attention. In January 2026 the MHRA issued a Drug Safety Update confirming it as a known, infrequent but potentially serious effect of GLP-1 medicines including tirzepatide. The signal to act on is severe stomach pain that builds rather than passes, may spread toward the back, and may or may not be accompanied by vomiting. If that happens, stop taking the medicine and seek emergency medical assessment the same day. Do not wait to see whether it settles.

Other situations that warrant prompt medical attention include: signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, rash spreading rapidly); symptoms suggesting gallbladder problems (sudden pain under the right ribs, especially after eating); and significant dehydration from persistent vomiting or diarrhoea, which can affect kidney function. Anyone with a history of medullary thyroid carcinoma or the rare inherited condition MEN2 should not use tirzepatide, and anyone with a personal or close-family history of thyroid tumours should discuss this explicitly with a prescriber before starting.

Suspected side effects can be reported directly to the MHRA through the Yellow Card scheme, this is how the regulator monitors safety signals in the real world, and patient reports genuinely contribute to post-market surveillance. Detailed contraindications are set out in the Mounjaro SmPC, held on the electronic Medicines Compendium. More specific risk information is covered on our Mounjaro risks page and in the broader tirzepatide safety overview.

What should you tell your prescriber, and how does the consultation address all of this?

A thorough safety screen before prescribing matters as much as the medicine itself. At nume, your consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not automated software) on the same day you submit it. That review covers your full medical history, current medications, contraindications and the specific risks relevant to you. If anything in your history requires clarification, the prescriber contacts you directly.

A few things to flag explicitly: any current oral contraceptive use (see the contraception note in our key facts above); any planned surgery, because anaesthetists need to know about tirzepatide beforehand; and any HRT that is taken orally, since NHS England advises considering transdermal alternatives during tirzepatide treatment for the same absorption reason that applies to the pill. These are not reasons to avoid treatment outright, they are conversations the prescriber can guide you through.

If you are already on Mounjaro through another provider and considering transferring, or if you have questions about whether it is right for your situation, checking your eligibility with our prescribers is the place to start. You can also read more about our clinical team on the clinical team page, or browse frequently asked questions if you want to read further before making a decision.